Skip to content

JBIO JBIO EBITDA

EBITDA at other companies

Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$11.7M+60.8%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$124.99M-119%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.51M-26.0%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$20.88M-43.7%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$53.62M+2.4%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Calculated from JBIO’s reported figures.

$43.4Mebit+
$9.0KDepreciation Depletion & Amortization
=-$43.44M

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's EBITDA?
JBIO (JBIO) reported EBITDA of -$43.44M in Q1 2026.
How has JBIO's EBITDA changed year-over-year?
JBIO's EBITDA decreased by 85.8% year-over-year, from -$23.38M to -$43.44M.
What is the long-term trend for JBIO's EBITDA?
Over 4 years (2021 to 2025), JBIO's EBITDA has grown at a 49.0% compound annual growth rate (CAGR), from -$23.01M to -$113.52M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.